EXALT1 Trial

In the landmark EXALT1 clinical study, our platform demonstrated for the first time that functional precision-oncology can improve patient outcome in a prospective interventional trial.

EXALT1 is the first-ever [1] prospective interventional study of its kind. Predictions made by the platform proposed which therapy would be most effective for late stage haematological cancer patients based on testing drug responses ex vivo in their own tissue samples.

EXALT-1 demonstrated real-world patient selection capabilities by achieving a 55% overall response rate and statistically significant improvement in progression free survival over the prior line of therapy for patients that were treated following the platform’s recommendation.

The Lancet Haematology